2-Hydroxymethyl-3,4,5-trihydroxy-6-methyl-piperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Hydroxymethyl-3,4,5-trihydroxy-6-methyl-piperidine
• 英文别名: 2-(Hydroxymethyl)-6-methylpiperidine-3,4,5-triol
• 化学式: C₇H₁₅NO₄
• 分子量: 177.2
• InChiKey: ZEWFPWKROPWRKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  93
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  咪唑 、 2-hydroxymethyl-3,4,5-trihydroxy-6-cyanopiperidine 、 etherealmethyl-magnesium iodide 生成 2-Hydroxymethyl-3,4,5-trihydroxy-6-methyl-piperidine
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Verwendung von 2-Hydroxymethylen-3,4,5-trihydroxypiperidinen als antivirale Mittel
  申请人：BAYER AG

  公开号：EP0315017A2

  公开（公告）日：1989-05-10

  Die Erfindung betrifft die Verwendung von bekannten, substituierten Hydroxypiperidinen, als antivirale Mittel in der Human- und Tiermedizin.

  本发明涉及已知取代的羟基哌啶作为抗病毒剂在人类和兽医中的应用。
• Synthesis of an azasugar and intermediates thereof
  申请人：DIPHARMA SA

  公开号：US11180454B2

  公开（公告）日：2021-11-23

  The present invention relates to a process for the preparation of migalastat of formula (I) and intermediates useful in the synthesis thereof. The process comprises the double reductive amination reaction of a compound of formula (VI).

  本发明涉及一种制备式（I）米加司他及其合成中间体的工艺。该工艺包括式（VI）化合物的双还原胺化反应。
• Derivate des 2-Hydroxymethyl-3,4,5-trihydroxy-piperidins, ihre Herstellung und sie enthaltende Arzneimittel
  申请人：BAYER AG

  公开号：EP0010745B1

  公开（公告）日：1983-04-13
• Treatment of CNS Disorders Associated with Mutations in Genes Encoding Lysosomal Enzymes
  申请人：Amicus Therapeutics, Inc.

  公开号：US20180133206A1

  公开（公告）日：2018-05-17

  Described is a method for treating an individual having a neurological disorder with an associated mutation or mutations in a gene encoding a lysosomal enzyme. Specifically, the individual is administered a specific pharmacological chaperone for the lysosomal enzyme which increases trafficking of the protein from the ER to the lysosome in neural cells, with or without concomitantly increasing enzyme activity in neural cells. Restoration of trafficking relieves cell stress and other toxicities associated with accumulation of mutant proteins. Restoration of enzyme activity relieves substrate accumulation and pathologies associated with lipid accumulation. In a specific embodiment, the neurological disorder is Parkinson's disease or parkinsonism which is associated with mutations in glucocerebrosidase.
• METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES
  申请人：AMICUS THERAPEUTICS, INC.

  公开号：US20180221357A1

  公开（公告）日：2018-08-09

  The present invention provides a method for increasing the activity of a mutant or wild-type α-glucosidase enzyme in vitro and in vivo by contacting the enzyme with a specific pharmacological chaperone which is a derivative of 1-deoxynojirimycin. The invention also provides a method for the treatment of Pompe disease by administration of chaperone small molecule compound which is a derivative of 1-deoxynojirimycin. The 1-deoxynojirimycin derivative is substituted at the N or C1 position. Combination therapy with replacement α-glucosidase gene or enzyme is also provided.